Page 137 - Recognizing axial spondyloarthritis - Janneke de Winter

13-39), did not assume that they will eventually develop SpA 22 (14-35) and consider SpA as a severe disease 66 (52-78).
Table 1. Baseline characteristics of participants
Age, mean (SD)
Gender male, n (%)
Back pain, n (%)
HLA-B27 positive, n (%)
BASDAI, median (IQR)
CRP, median (IQR)
ESR, median (IQR)
Enthesitis, n (%)
Arthritis, n(%)
Dactylitis, n (%)
Psoriasis, n (%)
Inflammatory bowel disease, n (%) Uveitis, n (%)
PREVENTIVE MEDICATION IN AXIAL SPA
Participants (n=106)
28.7 (5.6) 47 (44)
58 (55)
55 (52)
1.0 (0.5-2.0) 1.3 (0.7-2.7) 5 (2-9)
4 (4) 4 (4) 0
3 (3) 1 (1) 2 (2) 0
The percentage of participants willing to use preventive medication with 100% effectiveness causing no side effects varied between 63.2% (with 30% SpA risk) and 91.5% (with 70% SpA risk) (p<.0001, Figure 1A).
The percentage decreased depending on the possible occurrence of side effects. From 63.2% to 27.4% and 32.1% (with 30% SpA risk) if the medication would possibly cause mild side effects or infections respectively (p<.001, Figure 1B) and from 91.5% to 51.9% with 70% SpA risk if the medication would possibly cause infections (p<.0001, Figure 1C). When medication would cause a delay in SpA onset of 10 years (with 70% SpA risk), the percentage willing to use preventive medication decreased from 91.5% to 67.9% (p<.0001, Figure 1C).
The willingness to use preventive medication was negatively influenced by their own risk assessment of developing SpA (OR=1.17, p=.001). The GEE model showed no correlation between choice for preventive medication and age (OR 1.0, p=.96), HLA-B27 positivity (OR 1.45, p=.69) or the presence of back pain (OR 1.17, p=.58).
The willingness to use preventive medication was primarily influenced by the certainty of the risk to develop SpA (34.0%), followed by the risk of side effects (32.1%) and the effectiveness of the medication (25.5%). Medication costs (0.9%) and the route of administration (0%) had no influence.
Reactive arthritis, n (%)
HLA-B27: human leukocyte antigen B27; BASDAI: Bath Ankylosing Spondylitis Disease Activity Index; CRP: C-reactive protein; ESR: erythrocyte sedimentation rate, IQR: interquartile range
The willingness to use preventive medication
135
EIGHT